A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis

BACKGROUND: The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bactericidal activity, safety, and tolerability of a regi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Conde, Marcus B., Mello, Fernanda C. Q., Duarte, Rafael Silva, Cavalcante, Solange C., Rolla, Valeria, Dalcolmo, Margareth, Loredo, Carla, Durovni, Betina, Armstrong, Derek T., Efron, Anne, Barnes, Grace L., Marzinke, Mark A., Savic, Radojka M., Dooley, Kelly E., Cohn, Silvia, Moulton, Lawrence H., Chaisson, Richard E., Dorman, Susan E.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861335/
https://ncbi.nlm.nih.gov/pubmed/27159505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0154778
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars